Sugi Predict

Sugi Predict / Compounds / SCHEMBL14645907

SCHEMBL14645907

SCHEMBL14645907

CC(C)(O)c1ccc(C(=O)O)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 2/20 0.51
▸ EPHX2 P34913 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ RARB P10826 2/20 0.41
▸ RARA P10276 1/20 0.41
▸ RARG P13631 1/20 0.41
▸ AKR1C3 P42330 2/20 0.40
▸ AKR1C2 P52895 2/20 0.40
▸ SLC22A12 Q96S37 1/20 0.40
▸ ESRRG P62508 1/20 0.40
▸ APP P05067 1/20 0.40
▸ RXRB P28702 3/20 0.39
▸ RXRA P19793 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL495841 0.87 NR1H4 (0.60) NR1H4EPHX2KDM4EALDH1A1HPGD
SCHEMBL29607105 0.84 DGAT1 (0.58) NR1H4EPHX2KDM4EGAAAKR1C3
SCHEMBL6613345 0.84 DGAT1 (0.58) NR1H4EPHX2KDM4EGAAAKR1C3
Hydrochloric Acid SCHEMBL29607577 0.82 DGAT1 (0.56) NR1H4EPHX2KDM4EGAAAKR1C3
SCHEMBL18130727 0.82 NR1H4 (0.49) NR1H4EPHX2KDM4EALDH1A1HPGD
SCHEMBL283914 0.81 KDM4E (0.65) NR1H4EPHX2KDM4EALDH1A1HPGD
SCHEMBL17908058 0.81 RXRB (0.57) NR1H4EPHX2KDM4EALDH1A1HPGD
SCHEMBL19657820 0.81 NR1H4 (0.51) NR1H4EPHX2KDM4EALDH1A1HPGD
Trifluoroacetic Acid SCHEMBL29607210 0.80 DGAT1 (0.50) NR1H4EPHX2KDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL6498102 0.79 KDM4E (0.62) NR1H4EPHX2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4166557-B1 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES NOVARTIS AG (CH) 2026-05-06 — — EP disclosed
US-12441733-B2 Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors NOVARTIS AG (CH) 2025-10-14 — — US disclosed
EP-4467549-A2 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES Novartis AG (CH) 2024-11-27 — — EP disclosed
CN-118754858-A N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives 诺华股份有限公司 2024-10-11 — — CN disclosed
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE NOVARTIS AG (CH) 2024-07-04 — — US disclosed
US-20240158399-A1 N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives NOVARTIS AG (CH) 2024-05-16 — — US disclosed
EP-4304655-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE Novartis AG (CH) 2024-01-17 — — EP disclosed
EP-4166557-A1 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES Novartis AG (CH) 2023-04-19 — — EP disclosed
US-11613543-B2 Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors NOVARTIS AG (CH) 2023-03-28 — — US disclosed
US-20220387602-A1 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS AG (CH) 2022-12-08 — — US disclosed
US-9233111-B2 Pyrrolo pyrimidine derivatives NOVARTIS AG (CH) 2016-01-12 — — US disclosed
US-9233111-B2 Pyrrolo pyrimidine derivatives NOVARTIS AG (CH) 2016-01-12 — — US disclosed
EP-2729466-B1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2015-08-19 — — EP disclosed
EP-2729466-B1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2015-08-19 — — EP disclosed
US-20140243306-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2014-08-28 — — US disclosed
US-20140243306-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2014-08-28 — — US disclosed
US-20140243306-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2014-08-28 — — US disclosed
EP-2729466-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2014-05-14 — — EP disclosed
WO-2013008095-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2013-01-17 — — WO disclosed
WO-2013008095-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2013-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158399-A1 N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives PAH, REN, PKD1 NR1H4 763/4885EPHX2 2381/4885KDM4E 1112/4885
US-20220387602-A1 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE JMJD7, MDM2, IDE NR1H4 3130/4885EPHX2 755/4885KDM4E 2112/4885
US-20240216513-A1 FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE FASN, FABP1, SCD NR1H4 286/4885EPHX2 142/4885KDM4E 2757/4885
US-12441733-B2 Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors BTK, ABL1, LYN NR1H4 3722/4885EPHX2 2337/4885KDM4E 197/4885
US-20140243306-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES BTK, LCK, ZAP70 NR1H4 2847/4885EPHX2 2282/4885KDM4E 1348/4885
US-11613543-B2 Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors BTK, ABL1, JAK1 NR1H4 4554/4885EPHX2 2762/4885KDM4E 918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.